SLN
11:20 PM
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
silence-therapeutics.com
Catalyst Calendar
Tue, Aug 11, 2026
1 updatesMon, Aug 10, 2026
3 updatesSLN
4:01 PM
SLN
7:30 AM
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile
Trial Results • Phase 2silence-therapeutics.com
SLN
7:15 AM
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
silence-therapeutics.com
Sun, Aug 9, 2026
1 updatesSLN
5:00 PM
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera
Results Call • Phase 2silence-therapeutics.com